The cell and gene therapy (CGT) landscape is evolving at a pace that demands executive attention — and action. Beyond oncology, CGT indications are rapidly expanding into chronic disease states including cardiovascular disease, autoimmune conditions, neurological disorders, and metabolic diseases — fundamentally broadening the eligible patient population and the strategic imperative for health systems to act. Yet infrastructure readiness remains the critical bottleneck: health systems that fail to develop novel CGT delivery models risk being locked into costly, operationally complex pathways that limit scalability, strain capacity, and erode margin. This panel brings together leading pharmacy and health system executives to explore how forward-thinking organizations are seizing CGT not only as a clinical capability, but as a powerful revenue diversification strategy — one that attracts complex referral volume, unlocks manufacturer and payer partnerships, expands care into the outpatient and ambulatory care settings, and positions health systems as destination centers of excellence in an increasingly competitive market. For C-Suite leaders evaluating where to place their next strategic bet, this conversation is not optional — it is essential.